Intra-Cellular Therapies (NASDAQ: ITCI) reported Q4 EPS of ($0.75), $0.16 better than the analyst estimate of ($0.91).

“2018 was an important year for ITCI,” said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. “The FDA accepted for review our NDA for lumateperone for the treatment of schizophrenia. We also made significant progress in building our commercial infrastructure in preparation for potential launch, including the hiring of our commercial senior leadership team. In addition, we continued to advance our clinical and preclinical development programs including lumateperone for bipolar depression, ITI-214 and ITI-333 and look forward to providing additional updates on these programs in the year ahead.”

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.